Biomarkers associated with efficacy of first-line nivolumab vs. sorafenib in advanced hepatocellular carcinoma: results from the CheckMate 459 phase III trial. (PubMed, JHEP Rep) - Sep 20, 2026 - P3 | "These exploratory analyses from CheckMate 459 identified several candidate biomarkers that may be associated with efficacy of first-line nivolumab vs. sorafenib and support further studies to identify patients with advanced HCC who may benefit from programmed death-1 inhibition."
Biomarker • Journal • P3 data • Tumor mutational burden • Hepatocellular Cancer • Oncology • Solid Tumor • IFNG • PD-L1 • TMB
|
|
Amanda Cruz; Anthony B El-Khoueiry; Bruno Sangro; Ignacio Melero; Jaclyn Neely; James J Harding; Jin Yao; Marina Tschaika; Masatoshi Kudo; Olivier Rosmorduc; Richard S Finn; Robin Kate Kelley; Ruslan Novosiadly; Thomas Yau
|